Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  ANTA PHAR       

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2015 1,03 M
EBIT 2015 -36,9 M
Net income 2015 -37,2 M
Debt 2015 -
Yield 2015 -
Sales 2016 2,64 M
EBIT 2016 -50,4 M
Net income 2016 -50,6 M
Debt 2016 -
Yield 2016 -
P/E ratio 2015 -
P/E ratio 2016
Capi. / Sales 2015 103x
Capi. / Sales 2016 40,4x
Capitalization 106 M
More Financials
Company
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on developing and commercializing products to treat treat serious and life-threatening diseases, including lupus, lupus with glomerulonephritis, IgA nephropathy, and exocrine pancreatic insufficiency due to cystic... 
More about the company
Surperformance© ratings of ANTA PHAR
Trading Rating : Investor Rating : -
More Ratings
Latest news on ANTA PHAR
01/29 ANTHERA PHARMACEUTICALS : Change in Directors or Principal Officers (form 8-K)
01/22DJCigna Faces Halt in Medicare Advantage Enrollment -- 2nd Update
01/08 ANTHERA PHARMACEUTICALS : Change in Directors or Principal Officers, Financial S..
01/05 Anthera Pharmaceuticals Announces Appointment of Craig Thompson as President ..
01/05 Anthera Pharmaceuticals Announces Appointment of Craig Thompson as President ..
2015 ANTHERA PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL COND..
2015 ANTHERA PHARMACEUTICALS : Results of Operations and Financial Condition (form 8-..
2015 ANTHERA PHARMACEUTICALS : reports 3Q loss
More news
Sector news : Bio Therapeutic Drugs
05:01p GILEAD SCIENCES : to Participate in Two Upcoming Investor Conferences
12:04p VERTEX PHARMACEUTICALS : FDA declines to approve Vertex's Kalydeco in people wit..
11:36a LONZA : Kodiak Sciences Inc. and Lonza Announce Agreements for the Development a..
More sector news : Bio Therapeutic Drugs
Comments 
Advertisement
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions